BridgeBio Pharma, Inc. Common Stock (BBIO) is a publicly traded Healthcare sector company. As of May 20, 2026, BBIO trades at $67.69 with a market cap of $12.79B and a P/E ratio of -18.26. BBIO moved +3.41% today. Year to date, BBIO is -7.08%; over the trailing twelve months it is +102.37%. Its 52-week range spans $21.72 to $84.94. Analyst consensus is strong buy with an average price target of $109.00. Rallies surfaces BBIO's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
BridgeBio Pharma, Inc. Common Stock (BBIO) research on Rallies includes live charts, financials, analyst ratings, hedge fund holdings, politician trades, insider activity, news, AI research, and community context. BBIO moved +3.41% today. Analyst consensus is strong buy.
| Metric | Value |
|---|---|
| Price | $67.69 |
| Market Cap | $12.79B |
| P/E Ratio | -18.26 |
| EPS | $-3.73 |
| Dividend Yield | 0.00% |
| 52-Week High | $84.94 |
| 52-Week Low | $21.72 |
| Volume | 2.32M |
| Avg Volume | 0 |
| Revenue (TTM) | $579.96M |
| Net Income | $-729.88M |
| Gross Margin | 95.13% |
17 analysts cover BBIO: 0 strong buy, 17 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $109.00.